Genenta Science Q2 2025 Earnings Results & Report

Genenta Science EPS Results

• Actual EPS: -$0.10
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Genenta Science Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Genenta Science (NASDAQ:GNTA) S.p.A. (NASDAQ: GNTA) is a clinical-stage biotechnology company developing cell and gene therapies for cancer. The company’s approach uses a patient’s own hematopoietic stem cells, genetically modified outside the body to produce therapeutic proteins and deliver them to the tumor microenvironment.

Genenta’s lead investigational product, Temferon, is designed to generate interferon-alpha within solid tumors. The therapy is being studied primarily in glioblastoma, an aggressive form of brain cancer, with the goal of concentrating treatment in the tumor while limiting exposure to healthy tissues. Temferon is an investigational product and has not been approved for commercial use.

Genenta was established in Italy as a spin-off of the San Raffaele Scientific Institute in Milan, building on research associated with Professor Luigi Naldini and his laboratory. The company is headquartered in Milan and has pursued clinical development internationally, including in the United States and Europe. Pierluigi Paracchi has been associated with the company’s founding and executive leadership.